Edit Entry

David W Mullins, Ph.D.

Assistant Professor of Microbiology and Immunology

Microbiology and Immunology

BS, Biology (Microbiology), Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, VA
BS, Biochemistry,Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, VA
Ph.D., Microbiology and Immunology, Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, VA
Postdoctoral, Cancer Immunology and Immunotherapy, Carter Immunology Center, University of Virginia, Charlottesville, VA

Immunology Program
Molecular and Cellular Biology Graduate Programs
Norris Cotton Cancer Center

Contact Information:

HB7937, Rubin 733
Rubin 733, HB7937
Lebanon NH 03756

Office: Rubin 733
Phone: 603-653-9922
Email: David.W.Mullins@Dartmouth.edu

Professional Interests:

Cancer Immunology and Immunotherapy; Lymphocyte Trafficking and Infiltration of Tumors; Melanoma Cell Biology; Biological Therapies for Cancer; Melanoma Cell Biology

Rotations and Thesis Projects:

Current Students:
- Matthew P. Alexander, Ph.D. Candidate, Modulation of the melanoma microenvironment to enhance T cell infiltration.
- Amanda Costa, P.D. Student.


- Kiah Sanders, Ph.D. (Dr. David Bzik, Co-Mentor)

Lab Alumni:
- Eleanor Clancy-Thompson, PhD. (PhD, December 2014). Postdoctoral fellow, Dana Farber Cancer Institute, Boston, MA
- Tom Perekslis (technician, 2012-14). Jackson Labs, Bar Harbor, ME
Undergrad Research Students:
- Sasha Alcon (Junior/Senior Science Scholar, 2013-15).
- Julia Bratic (Presidential Science Scholar, 2013-15).
- Julianne Ivy (Presidential Science Scholar, 2013-15).
- Molly Harris-Jenkins, Ph.D. (PostDoc, 2012-2015). Research Scientist, Minerva Biotechnologies, Waltham, MA.

Grant Information:

Melanoma Research Alliance, Young Investigator Award, 2008
USPHS R01 CA134799, Role of CD8 T cell CXCR3 in the Regulation of Cancer, 2009-2014
Joanna M. Nicolay Melanoma Research Scholar Fellowship to Eleanor Clancy-Thompson, 2012-13
Joanna M. Nicolay Melanoma Research Scholar Fellowship to Matthew P. Alexander, 2013-14
Harry J. Lloyd Charitable Trust, Research Grant 2014-15
USPHS R03 CA188418, Combinatorial therapy of melanoma using T cells and site-specific Immunomodulators, 2015-2017.

Courses Taught:

- Medical Immunology and Virology(MICR111), Immunology Course Director
- Cellular and Molecular Basis of Immunity (MICR144), Tumor Immunology and Transplantation
- Cancer Immunology and Immunotherapy (Geisel Elective), Course Director

Selected Publications:


Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.
Bressler B, Bethel KP, Kleef R, Reynolds SL, Sutcliffe S, Mullins DW, Gunn H
Gastroenterol Res Pract. 2015;2015:231243. doi: 10.1155/2015/231243. Epub 2015 May 12.
PMID: 26064087

Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.
Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ, Huang YH, Mullins DW
Cancer Immunol Res. 2015 Aug;3(8):956-67. doi: 10.1158/2326-6066.CIR-15-0015. Epub 2015 Jun 5.
PMID: 26048575

The BRAF<sup>V600E</sup> inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE
Matrix Biol. 2015 May 16; pii: S0945-053X(15)00106-7. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.
PMID: 25989506

CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.
Jenkins MH, Brinckerhoff CE, Mullins DW
PLoS One. 2015;10(3):e0121140. doi: 10.1371/journal.pone.0121140. Epub 2015 Mar 23.
PMID: 25798946

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.
Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ
Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.
PMID: 25183499

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.
Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE
Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6.
PMID: 24460976

Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.
Clancy-Thompson E, King LK, Nunnley LD, Mullins IM, Slingluff CL Jr, Mullins DW
Cancer Immunol Res. 2013 Nov;1(5):332-9. doi: 10.1158/2326-6066.CIR-13-0084.
PMID: 24377099

Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.
Oliver JL, Alexander MP, Norrod AG, Mullins IM, Mullins DW
Pigment Cell Melanoma Res. 2013 Jul;26(4):571-9. doi: 10.1111/pcmr.12091. Epub 2013 Apr 11.
PMID: 23490134

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.
Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S
J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.
PMID: 23225891

Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.
Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE
J Cell Physiol. 2013 Apr;228(4):773-80. doi: 10.1002/jcp.24225.
PMID: 23001823